EUVIMEDEUVIMED entdecken
Systematische Übersicht

Safety Profile of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies

Giuseppe Querques, Michele Figus, Maddalena De Bernardo, Mario Damiano Toro, Magda Gharbiya, Valentina Gallinaro, Elena Strina, Vittorio Cacace, Massimo Nicolò

Ophthalmologica · 2025

DOI: 10.1159/000545987 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Ophthalmologica, 2025. Verfasst von Giuseppe Querques und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology University Vita-Salute, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Dexamethasone, Glucocorticoids, Macular Edema, Diabetes Complications. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 153 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With increasing experience using intravitreal dexamethasone implant (DEX-i), it has become a first-line therapy in patients with diabetic macular edema (DME), due mainly to its good efficacy profile. However, this treatment is not devoid of adverse events (AEs), which are predominantly transient and should be considered when administering it.

Methods

This systematic review without meta-analysis adhered to the guidelines delineated in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Systematic electronic searches were conducted in the PubMed, MEDLINE, Embase, and Google Scholar databases to identify real-world evidence (RWE) studies assessing the safety profile of DEX-i in patients with DME, covering the period from January 1, 2014, to March 1, 2024.

Results

This review included 76 RWE that evaluated the safety of DEX-i. Regarding intraocular pressure (IOP)-related AEs, these AEs were very heterogeneous and have included different definitions. The incidence of IOP-related AEs varied significantly from study to study, from 2% to almost 60%. In general, the peak IOP increase was typically observed 60 days post-DEX-i injection, followed by a decrease in the subsequent months. In most patients, these IOP-related AEs were successfully and efficiently managed with topical IOP-lowering medication, although some patients required additional treatments (i.e., laser or surgery). Regarding cataract development rates, the results were conflicting, with some studies showing rates ≥40%, while others reported rates of 0% or less than 5%. Additionally, current evidence showed the beneficial effects of DEX-i in eyes with DME that underwent cataract surgery. Other serious ocular AEs related to DEX-i were rare; indeed, the reported incidence rate of endophthalmitis ranged between 0.07% and 0.3%.

Conclusions

Overall, the main DEX-i-related AEs were elevation of IOP and cataract. Episodes of ocular hypertension were usually transient and successfully controlled with topical treatment. Additionally, repeated treatment with DEX-i in the same eye was not associated with IOP-related AEs, but it was with cataract-related AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneGlucocorticoidsMacular EdemaDiabetes ComplicationsCataractGlaucomaHumansTreatment OutcomeIntravitreal InjectionsDrug ImplantsIntraocular PressureIncidence

Stichwörter der Autor:innen

CataractDiabetic macular edemaIntraocular pressureIntravitreal dexamethasone implantSafety

Substanzen

DexamethasoneGlucocorticoidsDrug Implants

Autor:innen und Institutionen

  • Department of Ophthalmology University Vita-Salute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
  • Eye Unit, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" University of Salerno, Pisa, Italy.
  • Eye Clinic, Public Health Department, University of Naples Federico II, Naples, Italy.
  • Sapienza Università di Roma, Rome, Italy.
  • AbbVie S.r.l., Campoverde, Italy.

Zitieren

APA

Querques, G., Figus, M., De Bernardo, M., Toro, M. D., Gharbiya, M., Gallinaro, V., Strina, E., Cacace, V., & Nicolò, M. (2025). Safety Profile of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies. Ophthalmologica. https://doi.org/10.1159/000545987

Vancouver

Querques G, Figus M, De Bernardo M, Toro MD, Gharbiya M, Gallinaro V, et al. Safety Profile of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies. Ophthalmologica. 2025. doi:10.1159/000545987

BibTeX
@article{Querques2025,
  author = {Querques, Giuseppe and Figus, Michele and De Bernardo, Maddalena and Toro, Mario Damiano and Gharbiya, Magda and Gallinaro, Valentina and Strina, Elena and Cacace, Vittorio and Nicolò, Massimo},
  title = {Safety Profile of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies},
  journal = {Ophthalmologica},
  year = {2025},
  doi = {10.1159/000545987}
}
Kostenlos starten →